Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities.

Badlam JB, Bull TM.

Ther Adv Chronic Dis. 2017 Feb;8(2-3):47-64. doi: 10.1177/2040622317693218. Epub 2017 Mar 1. Review.

2.

Cyclooxygenase-2 Inhibition Limits Angiotensin II-Induced DNA Oxidation and Protein Nitration in Humans.

Pialoux V, Poulin MJ, Hemmelgarn BR, Muruve DA, Chirico EN, Faes C, Sola DY, Ahmed SB.

Front Physiol. 2017 Mar 10;8:138. doi: 10.3389/fphys.2017.00138. eCollection 2017.

3.

Increased serum levels of fractalkine and mobilisation of CD34+CD45- endothelial progenitor cells in systemic sclerosis.

Benyamine A, Magalon J, Cointe S, Lacroix R, Arnaud L, Bardin N, Rossi P, Francès Y, Bernard-Guervilly F, Kaplanski G, Harlé JR, Weiller PJ, Berbis P, Braunstein D, Jouve E, Lesavre N, Couranjou F, Dignat-George F, Sabatier F, Paul P, Granel B.

Arthritis Res Ther. 2017 Mar 20;19(1):60. doi: 10.1186/s13075-017-1271-7.

4.

A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy.

Ataya A, Cope J, Alnuaimat H.

J Clin Med. 2016 Dec 6;5(12). pii: E114. Review.

6.

Nitrite Prevents Right Ventricular Failure and Remodeling Induced by Pulmonary Artery Banding.

Hu J, Sharifi-Sanjani M, Tofovic SP.

J Cardiovasc Pharmacol. 2017 Feb;69(2):93-100. doi: 10.1097/FJC.0000000000000446.

PMID:
27851698
7.

Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis.

Jain S, Khera R, Girotra S, Badesch D, Wang Z, Murad MH, Blevins A, Schmidt GA, Singh S, Gerke AK.

Chest. 2017 Jan;151(1):90-105. doi: 10.1016/j.chest.2016.08.1461. Epub 2016 Sep 9.

PMID:
27615023
8.

D-optimal Design for Preparation and Optimization of Fast Dissolving Bosentan Nanosuspension.

Ghasemian E, Motaghian P, Vatanara A.

Adv Pharm Bull. 2016 Jun;6(2):211-8. doi: 10.15171/apb.2016.029. Epub 2016 Jun 30.

9.

Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension.

Monaco TJ, Davila CD.

Drug Des Devel Ther. 2016 May 18;10:1675-82. doi: 10.2147/DDDT.S88612. eCollection 2016. Review.

10.

Effects of bosentan on peripheral endothelial function in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.

Hirashiki A, Adachi S, Nakano Y, Kamimura Y, Shimokata S, Takeshita K, Murohara T, Kondo T.

Pulm Circ. 2016 Jun;6(2):168-73. doi: 10.1086/685715.

11.

Pulmonary hypertension: diagnostic approach and optimal management.

Hambly N, Alawfi F, Mehta S.

CMAJ. 2016 Aug 9;188(11):804-12. doi: 10.1503/cmaj.151075. Epub 2016 May 2. Review. No abstract available.

PMID:
27141034
12.

2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension.

Hsu CH, Ho WJ, Huang WC, Chiu YW, Hsu TS, Kuo PH, Hsu HH, Chang JK, Cheng CC, Lai CL, Liang KW, Lin SL, Sung HH, Tsai WC, Weng KP, Hsieh KS, Yin WH, Lin SJ, Wang KY.

Acta Cardiol Sin. 2014 Sep;30(5):401-44.

13.

Effect of dual pulmonary vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease: a retrospective analysis.

Monfredi O, Heward E, Griffiths L, Condliffe R, Mahadevan VS.

Open Heart. 2016 Apr 15;3(1):e000399. doi: 10.1136/openhrt-2016-000399. eCollection 2016.

14.

Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.

Kim JS, McSweeney J, Lee J, Ivy D.

Pediatr Crit Care Med. 2016 Mar;17(3 Suppl 1):S89-100. doi: 10.1097/PCC.0000000000000622. Review.

15.

Progress in the understanding and management of pulmonary arterial hypertension.

Chakrabarti AM, Mitchell JA, Wort SJ.

Glob Cardiol Sci Pract. 2015 Apr 4;2015:13. doi: 10.5339/gcsp.2015.13. eCollection 2015. No abstract available.

16.

Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide.

Lakshminrusimha S, Mathew B, Leach CL.

Semin Perinatol. 2016 Apr;40(3):160-73. doi: 10.1053/j.semperi.2015.12.004. Epub 2016 Jan 14. Review.

17.

Endothelin-1 Predicts Hemodynamically Assessed Pulmonary Arterial Hypertension in HIV Infection.

Parikh RV, Ma Y, Scherzer R, Heringer AS, Macgregor JS, Martin JN, Deeks SG, Ganz P, Hsue PY.

PLoS One. 2016 Jan 11;11(1):e0146355. doi: 10.1371/journal.pone.0146355. eCollection 2016.

18.

Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study.

Coyle K, Coyle D, Blouin J, Lee K, Jabr MF, Tran K, Mielniczuk L, Swiston J, Innes M.

Pharmacoeconomics. 2016 May;34(5):509-20. doi: 10.1007/s40273-015-0366-8.

19.

The limits of oral therapy in pulmonary arterial hypertension management.

Liu QQ, Jing ZC.

Ther Clin Risk Manag. 2015 Nov 23;11:1731-41. doi: 10.2147/TCRM.S49026. eCollection 2015. Review.

20.

Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases.

Adegunsoye A, Levy M, Oyenuga O.

Biomed Res Int. 2015;2015:929170. doi: 10.1155/2015/929170. Epub 2015 Oct 25. Review.

Supplemental Content

Support Center